by In2Pharma | Mar 3, 2023 | News
Europe In January 2023 EMA published a new Q&A with a clarification of Day 0 in the context of local literature review when it concerns physical copies of journals. Marketing authorisation holders (MAH) must review and assess reports of suspected adverse...
